IP Library Granted Patent US 9,408,405
Granted Patent B2
US 9,408,405 · App. 10/574,467 · Granted Aug 9, 2016

Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals

Inventors: Hubert Jean Marie François Gillessen (Lanaken, BE); Christian Rebiere (L'Herm, FR)
Assignee: Veijlen N.V.
A23K1/1625A23K1/165A23K1/184A23K1/188A23K1/1826A23K1/1893A61K31/404A61K31/405A61K31/4045A61K31/7056C07D209/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,408,405
App. No.
10/574,467
Granted
Aug 9, 2016
Kind
B2
Abstract

The present invention relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.

Claims (7)

1. A method of treating decreased ability for muscular exercise in a subject suffering from chronic fatigue syndrome, the method comprising:

administering to the subject a compound comprising indole acetic acid (IAA), 4-hydroxy-IAA, 4-methoxy-IAA, 5-hydroxy-IAA, 5-methoxy-IAA, 6-hydroxy-IAA, 6-methoxy-IAA, 7-hydroxy-IAA or 7-methoxy-IAA.

2. The method according to claim 1 , further comprising administering to the subject at least one amino acid.

3. The method according to claim 1 , wherein the compound is an active ingredient in a composition, and the composition comprises 1 to 100 mg of the compound.

4. The method according to claim 1 , wherein the compound is administered in a capsule.

5. The method according to claim 3 , wherein the composition comprises 10 to 90 mg of the compound.

6. The method according to claim 5 , wherein the composition comprises 40 mg of the compound.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2007
From: GILLESSEN, HUBERT JEAN MARIE FRANCOIS; REBIERE, CHRISTIAN
To: VEIJLEN N.V.
Reel/Frame 019347/0010 →
Continuity (1)
Related Publication 20080194553A1 · Aug 14, 2008